Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of Lytixar™ applied topically to uncomplicated skin infections.

Three dose levels of Lytixar™ (1%, 2% and 5%) versus placebo will be tested.


Clinical Trial Description

Treatment of uncomplicated, Gram-positive, skin infection may include application of antiseptics and desiccants, but most importantly topical antibiotics. Guidance on the use of antimicrobial therapies has been published, poor prescribing practices still exist which facilitate the development of bacterial strains resistant to available therapy. The issue of antimicrobial resistance is particularly important for Gram-positive cocci such as Staphylococcus aureus and Streptococcus pyogenes. Methicillin-resistant Staphylococcus aureus (MRSA) has been a problem for many years in the hospital setting, more recently community acquired MRSA (CA-MRSA) has emerged posing additional challenges to physicians managing skin infection. The medicinal product under development, Lytixar™, is a synthetic antimicrobial peptidomimetic agent with a membrane lysing mode of action. Lytixar™ has demonstrated activity against several Gram-positive and Gram-negative bacteria in vitro. The compound appears to be equally effective against antibiotic-resistant species such as methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci (VRE) and multi-resistant Pseudomonas isolates. The novel membrane lysing mode of action may result in a lower propensity to the development of resistance and to date Lytixar™ demonstrates no in vitro target-specific cross-resistance with other classes of antibiotics. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01223222
Study type Interventional
Source Lytix Biopharma AS
Contact
Status Completed
Phase Phase 2
Start date September 2010
Completion date February 2011

See also
  Status Clinical Trial Phase
Not yet recruiting NCT03441568 - In-home Use Test of the New Modified Diprobase Formulation to Assess the Safety and Tolerability in Infants and Children Under Physician's Control N/A
Completed NCT02595073 - Clinical Study to Evaluate the Efficacy and Safety of DSXS With Atopic Dermatitis Phase 3
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Not yet recruiting NCT03632174 - Evaluation and Comparison of 2 Cosmetic Investigational Products in Adults With Atopic Dermatitis N/A
Not yet recruiting NCT03661138 - A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis Phase 3
Completed NCT03304470 - A Study to Evaluate the Safety and Efficacy of ATx201 in Subjects With Moderate Atopic Dermatitis Phase 2
Not yet recruiting NCT03654755 - Study to Evaluate Long-Term Safety of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis Phase 2
Not yet recruiting NCT03559075 - Clinical vs. Anecdotal Evidence - Pediatric Atopic Dermatitis
Recruiting NCT02910791 - The Role of Bacterial Toxins in Human Skin Disease N/A
Recruiting NCT03051347 - Asthma and Atopic Dermatitis Validation of PROMIS Pediatric Instruments N/A
Completed NCT02844452 - Antipruritic Effect of Acupuncture in Patients With Atopic Dermatitis N/A
Completed NCT02865356 - Topical Solution for the Treatment of Atopic Dermatitis Phase 2
Completed NCT02914548 - Study of OPA-15406 Ointment in Patients With Atopic Dermatitis Phase 2
Completed NCT02260986 - Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis Phase 3
Withdrawn NCT01936194 - The Effects of Polyunsaturated Fatty Acids (PUFA) on Allergic/Atopic Dermatitis N/A
Completed NCT01927705 - Safety and Efficacy of FURESTEM-AD Inj. in Patients With Moderately Subacute and Chronic Atopic Dermatitis (AD) Phase 1/Phase 2
Recruiting NCT01692093 - KM110329 in Adult Patients With Atopic Dermatitis Phase 2
Terminated NCT01447758 - Safety, Tolerability and Pharmacokinetics of LEO 29102 Cream in Atopic Dermatitis. Phase 1
Completed NCT02094287 - Placebo Effect in the Treatment of Atopic Dermatitis N/A
Completed NCT01179880 - A Study of E6005 in Japanese Patients With Atopic Dermatitis Phase 1/Phase 2